Chief Executive Officer
Mr. Elam co-founded Rezolute, Inc. In addition to serving on the board of Rezolute, he also serves on the board of directors of Softhale in Brussels, Belgium and Savara, Inc. in Austin Texas.
Mr. Elam was previously CEO of AeroSurgical Limited, a European medical device company, which was subsequently acquired in a private transaction. Prior to AeroSurgical, Nevan had a very successful career at Nektar Therapeutics (NASDAQ: NKTR) where he served as SVP and Head of the Pulmonary Business Unit. While at Nektar, he re-shaped the pipeline and streamlined the organization. Further, during his tenure, he spun out Pearl Therapeutics to focus on treatments for asthma and COPD and Pearl was eventually acquired, in 2013, by AstraZeneca, for $1 billion. In addition, Nevan negotiated the acquisition of Aerogen, Inc. and later led a $10 million management buy out of Aerogen's Irish operations which is now a profitable business valued at more than $500 million. Finally, in 2008, he negotiated the sale of the pulmonary business unit at Nektar to Novartis for $200 million enterprise value.
Prior to his role at Nektar, Mr. Elam was CFO and co-founder of E2open, (NASDAQ: EOPN), an IT platform company serving the electronics and healthcare industries where, in addition to managing finance and corporate and business development, he established operations in five locations in Asia including Singapore, Kuala Lumpur, Taipei, Tokyo, and Seoul.
In the 1990s, Mr. Elam had a successful career at the venerable law firm of Wilson Sonsini Goodrich & Rosati in Palo Alto, California where he was a partner in the corporate practice. He worked with companies in a variety of industries including healthcare, where his clients ranged from large biotech organizations such as Genentech to small novel therapeutic companies in the US and Europe. Mr. Elam advised clients on a range of matters including debt and equity financings, FDA issues, acquisitions, partnerships and cross-border transactions. He also served clients such as Hewlett Packard and Sun Microsystems and notably, in 1997 he negotiated the sale of Steve Jobs' company, Next, to Apple.
Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.
Head of Clinical Development
Prior to joining Rezolute Bio, Dr. Roberts directed clinical development at Fibrogen, Inc, where he helped successfully launch and execute the global Phase 3 program and pharmaceutical partnership for a novel oral therapy for anemia associated with kidney disease, concluding the largest Phase 3 program ever conducted in CKD anemia, and resulting in global NDA filings. During his tenure, Fibrogen achieved the largest biotech IPO in the previous 10 years. From 2007 until 2012 Dr. Roberts held clinical development positions of increasing responsibility at Metabolex, Inc., where he developed novel therapies for metabolic diseases such as diabetes, dyslipidemia, NASH, and gout. His program and clinical leadership from IND through clinical proof-of-concept helped secure a global licensing and co-development agreement with a major pharmaceutical partner for a novel diabetes therapy. He is an inventor or author on more than 20 patents and publications in the fields of Endocrinology and Metabolism. Dr. Roberts received his B.S. in biochemistry from the University of California, San Diego and his medical degree Magna Cum Laude from Georgetown University. He completed residency in Internal Medicine and fellowship in Endocrinology at Stanford University, where he also now serves as Adjunct Associate Professor in the Division of Endocrinology.
Head of Clinical Operations
Erin O’Boyle joined Rezolute with nearly 20 years of operational and management experience across all phases of development covering several therapeutic areas, including oncology, anemia, idiopathic pulmonary fibrosis and rare disease indications. Prior to joining Rezolute, Erin worked at Fibrogen where she led all clinical outsourcing and governance activities from 2013 to 2018. Erin successfully contracted and managed all vendors for each clinical department which supported their various programs. These programs ranged from the largest Phase 3 global anemia program ever conducted resulting in NDA filings to a small Phase 2 rare orphan pediatric study in Duchene Muscular Dystrophy.
Before transitioning to a clinical lead in both contracting and governance, Erin was the Head of Clinical Operations at Heron Therapeutics from 2005 to 2013. During her time at Heron Therapeutics, Erin successfully led a clinical program from Phase 1 up through NDA approval of SUSTOL® (granisetron), an extended-release injection, for subcutaneous use for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of chemotherapy. To date, this is the largest CINV program ever conducted.
Erin’s excellent communication skills along with her multi-faceted capabilities in conducting clinical studies from end to end are a strong asset to Rezolute Bio and its emerging company profile.
Chief Financial Officer
Dr. Vendola brings two decades experience in healthcare corporate finance and strategy. As a Silicon Valley-based executive and NYC-based investment banker, he has helped companies navigate the capital markets and raise over $850 million.
Dr. Vendola previously served as Vice President of Competitive Strategy and Chief of Staff at Coherus BioSciences while the market cap exceeded $1 billion. His responsibilities included building relationships on Wall Street, on-boarding equity analysts, and executing multiple financings, which together raised $300 million. Prior, Dr. Vendola led business development at Threshold Pharmaceuticals. In this role, he contributed to the IPO onto the NASDAQ, the raise of over $100 million in the public markets, and a peak market cap exceeding $500 million.
Dr. Vendola served as an investment banker within the healthcare groups of Banc of America Securities (now BAML) and Chase (now JPMorgan). As a NYC-based investment banker, he executed multiple financings, which collectively raised $450 million.
Dr. Vendola received an MBA in finance from Northwestern's Kellogg School of Management, MD from Dartmouth Medical School, and BA in psychology from the College of the Holy Cross, where he graduated with honors. He completed an executive education program at Harvard Business School focused on strategic negotiations as well as a research fellowship in the Developmental Endocrinology Branch of the National Institutes of Health, where he was an author on multiple papers.
Chief Scientific Officer
As the author and inventor of over 70 publications and patents, Dr. Mantripragada is a widely recognized expert in long-acting injectable therapies with demonstrated success in the discovery and development of a number of commercially marketed drugs, including Exparel®, Depocyt® and Xcience®. He designed and developed Locemia Solutions' intranasal glucagon, the first potential needle-free rescue treatment for severe hypoglycemia that was recently acquired by Eli Lilly and Company. Previous to co-founding Rezolute, Inc., Dr. Mantripragada served as Vice President and Head of Research & Development at PR Pharmaceuticals, Inc. Throughout his career, Dr. Mantripragada has served as an advisor to several companies specializing in diabetes, cell based therapies and cardiovascular diseases. His prior roles include Director of Research & Development at Guidant Corporation (now part of Abbott Vascular), as well as Director of Research & Development and Vice President of Scientific Development at SkyePharma (now Pacira Pharmaceuticals). Prior to transitioning to the pharmaceutical industry, Dr. Mantripragada was Assistant Professor of Biochemistry at the University of Virginia School of Medicine. His training includes a Ph.D. in Molecular Biophysics from the Indian Institute of Science and postdoctoral research at the Max Planck Institute for Biophysical Chemistry in Germany.
Head of Operations
Prior to joining Rezolute Inc. in 2016, Mr. Deperro spent the past two decades in technical operations leadership roles within large pharma, biotech, generics and in a contract development and manufacturing capacity. A Mechanical Engineer from the University of Notre Dame and former US Army Officer, Mike's early career focused on the implementation of manufacturing and research infrastructure in the US and Ireland for companies including Schering Plough, Merck and Novartis. Transitioning from pharmaceutical engineering to operations management, Mike directed the startup of a generic parenterals business unit, focusing on plant establishment, product development and support of product launch for global markets. As Director of Manufacturing at Alkermes, Mike's manufacturing operation supported global sales of Risperdal® Consta®, the launch of Vivitrol® and delivery of Phase 3 supplies for Bydureon®, all commercialized controlled release formulations utilizing injectable microsphere technologies. These commercial manufacturing operations encompassed polymerization, bulk sterile microsphere manufacture and aseptic fill finish for US and ROW markets. Most recently, as General Manager for GMP Operations at Bend Research, and Vice President of Operations for Agere Pharmaceuticals, Mike led specialized teams charged with the delivery of early phase clinical supplies for complex, poorly soluble molecules in fast-paced multi-client environments. Mike's passion for leadership, integration of complex technologies and a strong belief in positive patient outcomes provide a strong foundation for the development of sustainable operations at Rezolute.
Head of Quality Assurance
Ms. Wong joined Rezolute, in March 2019, as the Senior Director, Quality Assurance. Prior to working at Rezolute, Ms. Wong held positions of increasing responsibility within quality at several companies, including Allergan, Inc., Novo Nordisk Delivery Technologies, Onyx Pharmaceuticals Inc. (acquired by Amgen, Inc.) and Puma Biotechnologies, Inc. With over two decades of experience in quality assurance, Ms. Wong has worked in both the pharmaceutical and medical device industries providing oversite for product development and commercialization activities. While at Onyx, Ms. Wong provided quality support and helped execute global Phase 3 and 4 programs for Kyprolis® and Nexavar®. Additionally, she helped successfully launch Blincyto® for the US market and Kyprolis® for US and global markets.
Ms. Wong earned her B.S. in Zoology from the University of California at Davis.
Head of Preclinical Development
Dr. Wang joined Rezolute, in 2014, with two decades biotech and pharmaceutical industry experience. She has broad knowledge and expertise in major aspects of small molecule and biologic therapeutic development ranging from target validation, drug discovery, preclinical development to clinical studies. She is experienced in managing core functional groups, overseeing contracted studies and leading multidisciplinary preclinical- and clinical-stage projects. Prior to joining Rezolute, Dr. Wang held positions with various responsibilities at Sugen (a subsidiary of Pharmacia acquired by Pfizer), Cymabay (formerly Metabolex), Takeda California, and NGM Bio. She has contributed to the development of two anticancer medicines that are currently on the market and is an author/inventor of over 40 publications and patents.
Dr. Wang received her Ph.D. in Physiology from University of Michigan and completed postdoctoral training in Cancer Research at Purdue University.
Chief Accounting Officer
With two decades experience in accounting and financial operations at public and private companies, Mrs. Miller’s expertise span S.E.C. reporting, financial planning and analysis, and regulatory compliance.
Prior to Rezolute, Mrs. Miller was Vice President of Accounting and Corporate Controller at Textainer Group Holding, while the net market cap exceeded $2.5 billion. She was instrumental in overseeing accounting operations as well as certain international endeavors. Prior to that, Mrs. Miller was Corporate Controller at Athoc, where she managed accounting operations and was a driving force in its successful acquisition by Blackberry. In 1990, Mrs. Miller started her career as a financial auditor within Price Waterhouse, now PricewaterhouseCoopers (PwC).
Mrs. Miller, a member of the American Institute of Certified Public Accounts (A.I.C.P.A.), obtained her Certified Public Accounting license in 1993 and earned her B.S. in Accounting from the University of Southern California.